Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

7.22
BATS BZX Real-Time Price
As of 12:42pm ET
 +0.13 / +1.83%
Today’s Change
5.02
Today|||52-Week Range
14.49
-14.15%
Year-to-Date
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
Apr 18 / Zacks.com - Paid Partner Content
Company News For Apr 12, 2018
Apr 12 / Zacks.com - Paid Partner Content
FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy
Apr 12 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close7.09
Today’s open7.24
Day’s range6.99 - 7.26
Volume11,750
Average volume (3 months)973,611
Market cap$271.0M
Data as of 12:42pm ET, 04/25/2018

Growth & Valuation

Earnings growth (last year)-39.67%
Earnings growth (this year)-12.53%
Earnings growth (next 5 years)--
Revenue growth (last year)+37.59%
P/E ratioNM
Price/Sales946.06
Price/Book2.29

Competitors

 Today’s
change
Today’s
% change
GERNGeron Corp-0.01-0.25%
BTXBioTime Inc-0.05-2.19%
EDGEEdge Therapeutics In...-0.03-2.25%
AGENAgenus Inc-0.00-0.14%
Data as of 12:43pm ET, 04/25/2018

Financials

Next reporting dateMay 8, 2018
EPS forecast (this quarter)-$0.74
Annual revenue (last year)$388.0K
Annual profit (last year)-$69.2M
Net profit margin-17,845.62%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Richard A. Fair
Chief Financial Officer &
Treasurer
Alan A. Musso
Corporate headquarters
Houston, Texas

Forecasts